What are the expected weight loss percentages for each oral orforglipron dose (6 mg, 12 mg, 24 mg, 36 mg) over approximately six months?

Weight Loss Percentages for Orforglipron

Orforglipron demonstrates dose-dependent weight loss ranging from 5.1% to 11.2% at 72 weeks in patients without diabetes, and 5.1% to 9.6% in patients with type 2 diabetes, with the highest dose (36 mg/17.2 mg once daily) producing the most substantial reductions.

Dose-Specific Weight Loss Data at 72 Weeks

Based on the FDA-approved FOUNDAYO (orforglipron) label from two pivotal Phase 3 trials 1:

In Patients WITHOUT Type 2 Diabetes (Trial 1):

• 6 mg (5.5 mg) dose: -7.4% mean weight loss (5.3% greater than placebo)
• 12 mg (9 mg) dose: -8.3% mean weight loss (6.2% greater than placebo)
• 36 mg (17.2 mg) dose: -11.1% mean weight loss (9.0% greater than placebo)

In Patients WITH Type 2 Diabetes (Trial 2):

• 6 mg (5.5 mg) dose: -5.1% mean weight loss (2.6% greater than placebo)
• 12 mg (9 mg) dose: -7.0% mean weight loss (4.5% greater than placebo)
• 36 mg (17.2 mg) dose: -9.6% mean weight loss (7.1% greater than placebo)

Clinically Meaningful Weight Loss Thresholds

The proportion of patients achieving clinically significant weight reduction increases substantially with higher doses 1:

≥5% Weight Loss (Without Diabetes):

• 6 mg: 59.6% of patients
• 12 mg: 63.1% of patients
• 36 mg: 71.5% of patients
• Placebo: 26.8%

≥10% Weight Loss (Without Diabetes):

• 6 mg: 32.5% of patients
• 12 mg: 39.8% of patients
• 36 mg: 54.5% of patients
• Placebo: 13.0%

≥15% Weight Loss (Without Diabetes):

• 6 mg: 14.3% of patients
• 12 mg: 20.1% of patients
• 36 mg: 35.9% of patients
• Placebo: 6.0%

≥20% Weight Loss (Without Diabetes):

• 6 mg: 5.9% of patients
• 12 mg: 8.9% of patients
• 36 mg: 18.4% of patients
• Placebo: 2.9%

Weight Loss in Patients With Type 2 Diabetes

Patients with diabetes experience somewhat attenuated but still clinically meaningful weight loss 1, 2:

≥10% Weight Loss (With Diabetes):

• 6 mg: 22.5% of patients
• 12 mg: 31.1% of patients
• 36 mg: 45.6% of patients
• Placebo: 9.2%

≥15% Weight Loss (With Diabetes):

• 6 mg: 6.7% of patients
• 12 mg: 14.4% of patients
• 36 mg: 25.9% of patients
• Placebo: 3.1%

Time Course of Weight Loss

Weight loss with orforglipron follows a predictable trajectory, with maximal reduction occurring around 72 weeks 1. The FDA label demonstrates that weight reduction begins during dose escalation and continues progressively through the full treatment period, with the steepest decline occurring in the first 24-36 weeks.

Shorter-Term Data (26-36 Weeks)

Phase 2 data at 36 weeks showed 3:

• 12 mg: -9.4% mean weight loss
• 24 mg: -12.6% mean weight loss
• 36 mg: -14.7% mean weight loss
• 45 mg: -12.8% mean weight loss

These shorter-term results suggest that weight loss continues to accrue beyond 36 weeks, with the 72-week data showing sustained but slightly lower percentages, consistent with the typical pattern of weight stabilization seen with GLP-1 receptor agonists.

Comparative Context

Orforglipron's weight loss efficacy at the highest dose (36 mg) approaches that of injectable semaglutide 2.4 mg, which produces approximately 10.3-12.6% weight loss at 68-104 weeks 4. This positions orforglipron as a potentially comparable oral alternative to injectable GLP-1 receptor agonists for weight management.

The dose-response relationship is clear and consistent across trials, with the 36 mg dose providing approximately 50% greater weight loss than the 6 mg dose in patients without diabetes 1, 5.

Important Clinical Considerations

Gastrointestinal adverse events are dose-dependent and occur predominantly during dose escalation, leading to treatment discontinuation in 5.3-10.3% of patients on orforglipron versus 2.7% on placebo 1, 5. The most common adverse events include nausea, vomiting, diarrhea, and constipation, which are typically mild to moderate in severity.

Weight loss effectiveness is consistent across demographic subgroups including age, sex, race, ethnicity, and baseline BMI 1. However, patients with type 2 diabetes consistently achieve approximately 2-3 percentage points less weight loss compared to those without diabetes at equivalent doses, likely reflecting the metabolic complexity of diabetes and potential concurrent use of weight-promoting medications.